Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ONO PHARMACEUTICAL : Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) (94.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/04/2012 | 04:15am CET

June 4th, 2012

ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

Bristol-Myers Squibb Company (hereinafter referred to as "BMS") announced the results from Phase 1 study in patients with non-small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC) to be published in New England Journal of Medicine (NEJM) and presented at 48th

Annual Meeting of the American Society of Clinical Oncology (ASCO), on June 2nd (US time).

ONO-4538/BMS-936558, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono Pharmaceutical Co., Ltd. (hereinafter referred to as "Ono") and Medarex, Inc. When Medarex, Inc. was acquired by BMS in

2009, it also granted BMS its rights to develop and commercialize the anti-PD-1 antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize ONO-4538/BMS-936558 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound.

BMS is conducting a Phase 2 study in RCC in North America and Europe, and plans to initiate registrational studies for anti-PD-1 this year in NSCLC and RCC, and late 2012, early 2013 for metastatic melanoma. On the other hand, Ono is conducting a Phase 2 study in metastatic melanoma in Japan, and plans to initiate clinical studies in RCC and NSCLC, taking account of the development status in United States and Europe.

Attached from the following page is the press release made by BMS for your information.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1

Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
12/08 ONO PHARMACEUTICAL : Encouraging Survival Observed With Opdivo (nivolumab) Plus ..
12/02 ONO PHARMACEUTICAL : OPDIVO® (nivolumab) Intravenous Injection Receives Approval..
11/29 ONO PHARMACEUTICAL : European Commission Approves Bristol-Myers Squibb's Opdivo ..
11/18 CELYAD : Announces Third Quarter 2016 Business Update
11/18 ONO PHARMACEUTICAL : Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) i..
11/16 ONO PHARMACEUTICAL : Price of cancer drug Opdivo to be halved in Feb. amid user ..
11/15 ONO PHARMACEUTICAL : Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Pr..
11/10 ONO PHARMACEUTICAL : Opdivo® (nivolumab) Intravenous Infusion Demonstrates a Sig..
10/24 ONO PHARMACEUTICAL : Filing of Patent Infringement Lawsuit against MSD K.K. (81...
10/20 ONO PHARMACEUTICAL : Merus Receives Milestone Payment from Ono Pharmaceutical fo..
More news
Sector news : Generic Pharmaceuticals
04:31pDJASTRAZENECA : FDA Accepts License Application for Durvalumab
02:05pDJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
11/17 Opdivo's price halved in Japan
11/14 Bristol's Bid To Get Ahead In Head And Neck
10/03 A European Biotech Stock Basket For 2016 - Update
Advertisement
Financials ( JPY)
Sales 2017 256 862 M
EBIT 2017 -
Net income 2017 54 679 M
Finance 2017 107 438 M
Yield 2017 1,79%
P/E ratio 2017 22,92
P/E ratio 2018 23,12
EV / Sales 2017 4,97x
EV / Sales 2018 4,80x
Capitalization 1 383 235 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 3 426  JPY
Spread / Average Target 46%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-45.66%12 081
SUN PHARMACEUTICAL IND..-18.89%24 003
OTSUKA HOLDINGS CO LTD2.77%21 705
ASPEN PHARMACARE HOLDI..-11.51%9 015
SHANGHAI FOSUN PHARMAC..-0.77%8 009
TAISHO PHARMACEUTICAL ..7.08%7 148
More Results